Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation

Stroke

Volumn 39, Issue 6, 2008, Pages 1901-1910

  Hart, Robert G ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Atrial fibrillation; Clinical prediction rules; Risk factors; Stroke

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL FEATURE; DIABETES MELLITUS; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; MALE; NONVALVULAR ATRIAL FIBRILLATION; PATIENT SELECTION; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; STANDARDIZATION; STATISTICAL ANALYSIS; STROKE; TRANSIENT ISCHEMIC ATTACK; AGE; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; METHODOLOGY; MULTICENTER STUDY; PREDICTION AND FORECASTING; PROGNOSIS; REVIEW; RISK FACTOR; STANDARD; STATISTICS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; COMORBIDITY; HUMANS; MULTICENTER STUDIES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 46249089014     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.501825     Document Type: Article

References (42)

1. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: A systematic review. Neurology. 2007;69:546-554.
2. Pearce LA, Hart RG, Halperin JL. Stratifying stroke risk in atrial fibrillation: Assessment of three clinical schemes for primary prevention. Am J Med. 2000;109:45-51.
3. Go AS, Hylek EM, Phillips KA, Borowsky LH, Henault LE, Chang Y, Selby JV, Singer JE. Implications of stroke risk criteria on the anticoag-ulation decision in nonvalvular atrial fibrillation: the Antcoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation. 2000;102: 11-13.
4. Laguna P, Martin A, Del Arco C, Millan I, Gargantilla P on behalf of the investigators in the Spanish Atrial Fibrillation in Emergency Medicine Study Group. Differences among clinical classification schemes for predicting stroke in atrial fibrillation: Implications for therapy in daily practice. Academic Emerg Med. 2005;12:828-834.
5. Nieuwlaat R, Capucci A, Lip GYH, Olsson SB, Prins MH, Nieman FH, Lopez-Sendon J, Vardas PE, Aliot E, Santini M and Crijns HJGM on behalf of the Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Study Survey on Atrial Fibrillation. Eur Heart J. 2006;27:3018 -3028.
6. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154: 1449-1457.
7. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis. 1995;5:147-157.
8. van Latum JC, Koudstaal PJ, Venables GS, van Gijn J, Kappelle LJ. Algra A for the European Atrial Fibrillation Trial (EAFT) Study Group. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke with nonrheumatic atrial fibrillation. Stroke. 1995;16:801-806.
9. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation. A prospective study of 1,066 patients from three clinical trials. Arch Intern Med. 1998;158:1316 -1320.
10. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke. 1999;30:1223-1229.
11. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey J-Y, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - Executive summary. Circulation. 2006;114:e257-e354.
12. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results of the National Registry of Atrial Fibrillation. JAMA. 2001;285: 2864-2870.
13. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. The Sixth ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2001;119: 194S-206S.
14. van Walraven C, Hart RG, Wells GA, Petersen P, Koudstaal PJ, Gullov AL, Hellemons BSP, Koefed BG, Laupacis A. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med. 2003;163:936-943.
15. Wang TJ, Massaro JM, Levy D, Vasan RV, Wolf PA, D'Agostino RB, Larson MG, Kannel WB, Benjamin EJ. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. The Framingham Study. JAMA. 2003;290:1049-1056.
16. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126: 429S-456S.
17. Lip GYH, Lane D, van Walraven C, Hart RG. Additive role of plasma von Willebrand Factor levels to clinical factors for risk stratification in patients with atrial fibrillation. Stroke. 2006;37:2294 -2300.
18. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. J Am Coll Cardiol. 2001;38:1231-1265.
19. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation. The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study. Circulation. 2005;112:1687-1691.
20. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BSP, Petersen PJ. Selecting patients with atrial fibrillation for anticoagulation. Stroke risk stratification in patients taking aspirin. Circulation. 2004;110: 2287-2292.
21. Feinberg WM, Kronmal RA, Newman AB, Kraut MA, Bovill EG, Cooper L, Hart RG. Stroke and atrial fibrillation in a population-based cohort. The Cardiovascular Health Study. J Gen Intern Med. 1999;14:56-59.
22. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-638.
23. Stroke Prevention in Atrial Fibrillation Investigators. Patients with non-valvular atrial fibrillation at low-risk of stroke during treatment with aspirin: The Stroke Prevention in Atrial Fibrillation III Study. JAMA. 1998;279:1273-1277.
24. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE. Anticoagulation therapy for stroke prevention in atrial fibrillation. How well do randomized trials translate into clinical practice? JAMA. 2003;290:2685-2692.
25. Healey JS, Hart RG, Pogue J, Pfeffer MA, Hohnloser SH, De Caterina R, Flaker G, Yusuf S, Connolly SJ. Risks and benefits of oral anticoagu-lation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: The Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE-W). Stroke. 2008;39:1482-1486.
26. Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE; for the ATRIA Study Group. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008;51:810-815.
27. Kalra L, Perez I, Melbourn A. Risk assessment and anticoagulation for primary stroke prevention in atrial fibrillation. Stroke. 1999;30: 1218-1222.
28. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet. 1998;352:1167-1171.
29. Thomson R, McElroy H, Sudlow M. Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: variation in content and implications for treatment. BMJ. 1998;316:509-513.
30. Laupacis A, Sekar N, Stiell IG. Clinical prediction rules. A review and suggested modifications of methodological standards. JAMA. 1997;277: 488-494.
31. Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules. Applications and methodological standards. N Engl J Med. 1985;313: 793-799.
32. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med. 2000;19:453-473.
33. Arima H, Hart RG, Colman S, Chalmers J, Anderson C, Rodgers A, Woodward M, Neal B. Perindopril-based blood pressure lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or TIA. Stroke. 2005;36:2164-2169.
34. ACTIVE Writing Committee on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation. Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE-W). Lancet. 2006;367:1903-1912.
35. Sherman DG, Kim SG, Boop BS, Corley SD, DiMarco JP, Hart RG, Haywood LJ, Hoyte K, Kaufman ES, Kim MH, Nasco E, Waldo AL, and the NHLBI AFFIRM Investigators. The occurrence and characteristics of stroke events in the AFFIRM Study. Arch Intern Med. 2005;165: 1185-1191.
36. Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximegalatran compared with warfarin in patients with non-valvular atrial fibrillation: randomized controlled trial. Lancet. 2003;362:1691-1698.
37. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA. 2005;293:690-698.
38. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Seward JB, Bailey KR, Iwasaka T, Tsang TSM. Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000. Report of a community-based study. Stroke. 2005;36:2362-2366.
39. Lip GYH, Frison L, Grind M on behalf of the SPORTIF Investigators. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J. 2007;28:752-759.
40. Lakshiminaryan K, Solid C, Anderson DC, Herzog CA. Validation of the CHADS2 stroke risk classification in Medicare data. Stroke. 2006;37:671 (abstract).
41. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, Radford MJ. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713-719.
42. Man-Son-Hing M, Gage BF, Montgomery AH, Howitt A, Thomson R, Devereaux PJ, Protheroe J, Fahey T, Armstrong D, Laupacis A. Preference-based antithrombotic therapy in atrial fibrillation: Implications for clinical decision making. Med Decis Making. 2005;25: 548-559.